NTLA-5001
Acute Myeloid Leukemia (AML)
Key Facts
About Intellia Therapeutics
Intellia Therapeutics is a pioneer in the development of CRISPR/Cas9-based therapeutics, aiming to cure severe genetic and other diseases through precise genome editing. The company has achieved significant milestones, including the first-ever clinical data demonstrating in vivo CRISPR genome editing in humans. Its strategy leverages a dual-platform approach, developing both in vivo (systemically administered) and ex vivo (cell-based) therapies, with key partnerships including Regeneron and Novartis to advance its pipeline.
View full company profileTherapeutic Areas
Other Acute Myeloid Leukemia (AML) Drugs
| Drug | Company | Phase |
|---|---|---|
| Galinpepimut-S (GPS) | SELLAS Life Sciences | Phase 2/3 |
| SLS009 (GFH009) | SELLAS Life Sciences | Phase 1/2 |
| UCART123 | Cellectis | Phase 1 |
| Iadademstat (ORY-1001) | Oryzon Genomics | Phase 2 |
| MP0533 | Molecular Partners | Phase 1/2 |
| SEL24 (MEN1703) | Selvita | Phase 1/2 |
| Selinexor | Karyopharm Therapeutics | Clinical Trials |
| NEX-20 (azacitidine) | Nanexa AB | Phase 1 |
| SENTI-202 | Senti Biosciences | Phase 1 |
| motixafortide (BL-8040) | BioLineRx | Phase 2a |
| ACD-101 | Advanced Cellular Dynamics | Phase 1 |
| ABD-3001 | Advanced Biodesign | Phase 1 |